37 results on '"Verdier, M. C."'
Search Results
2. Use of very-high-dose olanzapine in treatment-resistant schizophrenia
- Author
-
Batail, J.-M., Langrée, B., Robert, G., Bleher, S., Verdier, M.-C., Bellissant, E., Millet, B., and Drapier, D.
- Published
- 2014
- Full Text
- View/download PDF
3. La température de conservation du cisatracurium ne modifie pas le délai d’action : étude randomisée, en double insu
- Author
-
Lorne, E., Nuzzo, D., Suzanne, S., Walczak, K.-A., Perret, C., Laigle, C., Mattei, N., Dimov, E., Petiot, S., Godart, J., Pila, C., Verdier, M.-C., Chourbaggi, C., Diouf, M., Friggeri, A., Mahjoub, Y., and Dupont, H.
- Published
- 2012
- Full Text
- View/download PDF
4. Therapeutic drug monitoring of ruxolitinib in graft versus host disease in pediatric allogenic hematopoietic stem cell transplant recipients: A multicenter retrospective study
- Author
-
Franck, B., Lemaitre, F., Verdier, M. C., Felber, M., Rialland, F, Bellissant, E., Gandemer, V., Tron, C., CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Génétique et Développement de Rennes (IGDR), and Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
pediatrics ,ruxolitinib ,[SDV]Life Sciences [q-bio] ,graft versus host disease - Abstract
International audience; Meeting Abstract PS-103
- Published
- 2022
5. An easy, fast and inexpensive multiplex pharmacogenetics assay to simultaneously analyze 17 clinically relevant genetic polymorphisms in CYP3A4, CYP3A5, CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1 and VKORC1 genes
- Author
-
Tron, C., Bouvet, R., Verdier, M. C, Lamoureux, F., Hennart, B., Dubourg, Christèle, Bellissant, E., Galibert, Marie-Dominique, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], CHU Rouen, Normandie Université (NU), CHU Lille, Institut de Génétique et Développement de Rennes (IGDR), and Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
multiplex ,[SDV]Life Sciences [q-bio] ,CYP450 ,personalized medicine ,panel ,pharmacogenetics - Abstract
International audience; Meeting Abstract PM1-019
- Published
- 2022
6. Contribution of voriconazole phenotyping to patient management
- Author
-
Boglione-Kerrien, C., Morcet, J., Lalanne, S., Franck, B., Tron, C., Taieb, F., Couette, A., Verdier, M. C., Bellissant, E., Lemaitre, F., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
N-oxide-voriconazole ,therapeutic drug monitoring ,[SDV]Life Sciences [q-bio] ,voriconazole - Abstract
International audience; Meeting Abstract PS-074
- Published
- 2022
7. Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient
- Author
-
Lemaitre, F., Jezequel, C., Verdier, M.-C., Dermu, M., Boglione-Kerrien, C., Boudjema, K., and Bellissant, E.
- Published
- 2015
- Full Text
- View/download PDF
8. Deciphering pharmacogenetic-whole blood/intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients
- Author
-
Tron, C., Woillard, J. B., Houssel-Debry, P., David, V., Rayar, M., Balakirouchenane, D., Debord, J., Jezequel, C., Camus, C., Roussel, M., Boudjema, K., Verdier, M. C., Bellissant, E., Lemaitre, F., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Limoges, Ciblage individuel et prévention des risques de traitements immunosupresseurs et de la transplantation (IPPRITT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
liver transplantation ,[SDV]Life Sciences [q-bio] ,pharmacodynamics ,modeling ,Tacrolimus ,pharmacogenetics - Abstract
International audience; Meeting Abstract PS-161
- Published
- 2021
9. Redefining therapeutic drug monitoring of tacrolimus in liver transplantation: can we target trough concentrations below 7 ng/ml during the first month?
- Author
-
Lemaitre, F., Tron, C., Jezequel, C., Lalanne, S., Verdier, M. C., Bardou-Jacquet, E., Camus, C., Boudjema, K., Bellissant, E., Rayar, M., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
liver transplantation ,therapeutic drug monitoring ,[SDV]Life Sciences [q-bio] ,outcome ,immunosuppressive drugs ,tacrolimus - Abstract
International audience; Meeting Abstract PM-064
- Published
- 2021
10. Pharmacokinetic-pharmacodynamic profile in patients treated with ceftaroline: A retrospective study
- Author
-
Lalanne, S., Revest, M., Taieb, F., Benezit, F., Tron, C., Boglione, C., Lemaitre, F., Bellissant, E., Verdier, M. C., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract PS-188
- Published
- 2021
11. A case report of a therapeutic drug monitoring-guided sofosbuvir-velpatasvir crushed treatment
- Author
-
Lalanne, S., Tron, C., Verdier, M. C., Jezequel, C., Mercerolle, M., Pronier, C., Guyader, D., Bellissant, E., Lemaitre, F., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract PS-191
- Published
- 2021
12. Validation of a high-performance liquid chromatography-tandem mass spectrometry method for the quanYtification of beta-lactams in cardiac valves
- Author
-
Lalanne, S., Revest, M., Tron, C., Boglione, C., Lemaitre, F., Bellissant, E., Verdier, M. C., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract PS-189
- Published
- 2021
13. Tacrolimus is a P-glycoprotein but not a multidrug resistance-associated proteins or a concentrative nucleoside transporter 3 substrate
- Author
-
Coste, G., Le Vee, M., Tron, C., Verdier, M. C., Fardel, O., Lemaitre, F., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], EHESP-Irset (EHESP-Irset), École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
individualization ,[SDV]Life Sciences [q-bio] ,lymphocyte ,tacrolimus ,drug transporter ,transplantation - Abstract
International audience; Meeting Abstract PS-016
- Published
- 2021
14. Efficacy of generic meropenem products in combination with colistin in carbapenemase-producing Klebsiella pneumoniae experimental osteomyelitis
- Author
-
Tattevin, P., primary, Dinh, A., additional, Ghout, I., additional, Mouton, W., additional, Verdier, M.-C., additional, Laurent, F., additional, Lemaitre, F., additional, Gatin, L., additional, Saleh-Mghir, A., additional, and Crémieux, A.-C., additional
- Published
- 2020
- Full Text
- View/download PDF
15. Biological and Hemodynamic Effects of Low Doses of Fludrocortisone and Hydrocortisone, Alone or in Combination, in Healthy Volunteers With Hypoaldosteronism
- Author
-
Laviolle, B, Le Maguet, P, Verdier, M-C, Massart, C, Donal, E, Lainé, F, Lavenu, A, Pape, D, and Bellissant, E
- Published
- 2010
- Full Text
- View/download PDF
16. Pharmacokinetic and pharmacodynamic profile of beta-lactam antibiotics in patients treated for infective endocarditis a five-year retrospective study
- Author
-
Lalanne, S., Revest, M., Taieb, F., Petitcollin, A., Tron, C., Boglione-Kerrien, C., Verdier, M. C., Bellissant, E., Lemaître, F., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
17. Beta-lactams and Proton Pump Inhibitors a new example of renal transporters mediated drug-drug interaction
- Author
-
Lalanne, S., Verdier, M. C., Le Vee, M., Lemaitre, F., Fardel, O., Bellissant, E., CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2019
18. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies
- Author
-
Lemaitre, Florian, Le Guillou, Adrien, Pugliese, Pascal, Raffi, François, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Dramé, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé, Orticoni, M, Soavi, M, Luquet- Besson, I, Ressiot, E, Carta- Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A., Monclar, M, Ritleng, A, Ivanova, A., Blanco-Betancourt, C, Lions, C., Poizot-Martin, I., Dhiver, C, Saadia Mokhtari, M, Menard, A., Tissot Dupont, H, Toméi, C, Meddeb, L., Belkhir, A., Ravaux, I., Alvarez, M., Biezunski, N, Debard, A., Delpierre, C, Lansalot, P, Lelievre, L., Martin-Blondel, G., Piffaut, M, Porte, L., Saune, K, Delobel, P., Breaud, S., Ceppi, C, Chirio, D, Cua, E, Dellamonica, P., Demonchy, E, De Monte, A, Durant, J., Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V., Bernaud, C, Billaud, E., Biron, C, Bonnet, B, Bouchez, S, Boutoille, D., Brunet-Cartier, C, Deschanvres, C, Gaborit, B., Hall, N, Le Turnier, P., Morineau, P, Reliquet, V., Sécher, S, Cavellec, M, Soria, A., Ferre, V., André-Garnier, E., Rodallec, A., Lefebvre, M, Grossi, O, Aubry, O., Amazzough, K., Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C., Consigny, P, Danion, F., Dureault, A, Duvivier, C., Goesch, J, Guery, R., Henry, B., Jidar, K, Lanternier, F., Loubet, P., Lortholary, O., Louisin, C, Lourenco, J, Parize, P., Pilmis, B., Touam, F, Valantin, M, Tubiana, R., Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C, Cabié, André, Abel, S., Pierre-François, S, Pasquier, J., Guitteaud, K, Turmel, J, Illiaquer, M, Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S., Rey, D., Chirouze, C., Gardiennet, Q, Berger, J, N’Guyen, Y, Lambert, D., Hentzien, M., Lebrun, D., Brunet, A, Kmiec, I, Brodard, V, Chidiac, C., Ferry, T., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I, Lippmann, J, Braun, E, Koffi, J, Longuet, C., Guéripel, V, Augustin-Normand, C, Brochier, C, Degroodt, S, Atoui, N, Le Moing, V., Makinson, A., Meftah, N., de Boever, C Merle, Montes, B, Montoya Ferrer, A, Reynes, J., Andre, M., Boyer, L, Bouillon, M, Delestan, M, May, T, Hocqueloux, L, Prazuck, T., Gubavu, C, Sève, A, Maka, A, Boulard, C., Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E., Lerolle, N., Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C., Lariven, S, gervais, a, Lescure, F., Matheron, S., Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, c, Descamps, D., Peytavin, G., Yazdanpanah, Y., Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat-Delon, S, Chapplain, J, Bénézit, F., Dupont, M., Poinot, M., MAILLARD, A, Pronier, C., Guennoun, C, Poisson-Vanier, M, Jovelin, T., Sinteff, J, Arvieux, C, Botelho-Nevers, E., Gagneux-Brunon, A., Frésard, A., Lucht, F., Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A, Choisy, P, Huleux, T., Lafon-Desmurs, B., Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M., Hoen, B., Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P., Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Boglione-Kerrien, C., Picard, S., Tron, C., Nimubona, S., Gangneux, J.-P., Lalanne, S., Lemaître, F., Bellissant, E., Verdier, M.-C., Petitcollin, A., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nice (CHU Nice), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), DDSIS 76, Institut national de recherche et de sécurité (Vandoeuvre lès Nancy) (INRS ( Vandoeuvre lès Nancy)), Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Laboratoire de Physique et Chimie Quantique, Université Mouloud Mamerri, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Département de Physique Nucléaire (ex SPhN) (DPHN), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut des Matériaux, de Microélectronique et des Nanosciences de Provence (IM2NP), Aix Marseille Université (AMU)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS), Département Etude des Réacteurs (DER), CEA-Direction de l'Energie Nucléaire (CEA-DEN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Science et Technologie du Lait et de l'Oeuf (STLO), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université Paris Descartes - Paris 5 (UPD5), Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Weill Cornell Medicine [Qatar], Institut Rayonnement Matière de Saclay (IRAMIS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], GEOMA, Université de Vigo, Universidate de Vigo, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Laboratoire d'aérologie (LA), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Service des Maladies Infectieuses, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France, parent, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Equipe 15, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Faculté des Mathématiques et des Sciences de la Matière, Université Kasdi Merbah Ouargla, Laboratoire de Géochimie Isotopique Environnementale (GIS) / Université de Nîmes (GIS), Université de Nîmes (UNIMES)-Centre National de la Recherche Scientifique (CNRS), CHU UCL Namur, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Unité des Rickettsies et pathogènes émergents (URPE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Etienne, University Hospital and University Jean Monnet, Centre Hospitalier Tourcoing, CHU de Fort de France, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Laboratoire de Génie des Procédés et Matériaux - EA 4038 (LGPM), CentraleSupélec, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Posaconazole ,Antifungal Agents ,[SDV]Life Sciences [q-bio] ,Administration, Oral ,Dat’AIDS cohort ,Pharmacology ,030226 pharmacology & pharmacy ,Gastroenterology ,0302 clinical medicine ,MESH: Drug Monitoring ,Medicine ,Prospective Studies ,Haematological malignancies ,media_common ,MESH: Aged ,Hematology ,MESH: Middle Aged ,medicine.diagnostic_test ,General Medicine ,Middle Aged ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,90-90-90 target ,3. Good health ,Posaconazole oral tablet ,Oncology ,Quartile ,MESH: Young Adult ,Hematologic Neoplasms ,MESH: Administration, Oral ,Female ,Drug Monitoring ,Antifungal prophylaxis ,Safety ,medicine.drug ,Tablets ,Drug ,Adult ,medicine.medical_specialty ,media_common.quotation_subject ,030106 microbiology ,Therapeutic drug monitoring ,03 medical and health sciences ,Young Adult ,Pharmacokinetics ,Invasive fungal infections ,Internal medicine ,Pharmacovigilance ,primary HIV infection ,cascade of care ,Humans ,Aged ,MESH: Humans ,business.industry ,MESH: Adult ,TasP ,Triazoles ,MESH: Antifungal Agents ,MESH: Prospective Studies ,MESH: Male ,MESH: Triazoles ,MESH: Tablets ,business ,Liver function tests ,MESH: Female ,MESH: Hematologic Neoplasms - Abstract
International audience; PurposePosaconazole is a triazole antifungal widely used for prophylaxis of invasive fungal disease (IFI). Posaconazole tablets allow reaching higher plasma levels than the oral suspension, but safety data with this formulation in real life are scarce. This study aimed at evaluating the safety profile, the pharmacokinetic variability, and the concentration–toxicity relationship of posaconazole tablets in patients with haematological malignancies.MethodsSixty neutropenic patients treated with posaconazole tablets for prophylaxis of IFI were prospectively included in the study. Adverse drug reactions (ADR) were recorded and analyzed by the Regional Pharmacovigilance Centre to assess posaconazole implication. Blood samples were drawn once a week and plasma trough concentrations (C min) were assayed by LC–MS/MS. The rates of ADR by quartile of C min were compared.ResultsEighteen patients (30%) experienced at least one ADR attributed to posaconazole. Liver function test (LFT) abnormalities were encountered in 20% of patients and resulted in four (6.7%) treatment discontinuations. Posaconazole median (range) C min was 1.36 (< 0.1–3.44) µg/mL (inter-patient CV = 43.9%). During follow-up, 28.6% of patients had at least one concentration < 0.7 µg/mL, and 35.7% had at least one concentration > 2 µg/mL. Rates of ADR by quartile of C min were not different.ConclusionsPosaconazole was well tolerated; however, LFT abnormalities were frequent. ADR occurrence was not linked to posaconazole exposure. Because posaconazole concentrations were highly variable, TDM can be helpful to avoid underexposure to the drug and increase its efficacy in preventing IFI. Conversely, a large proportion of patients was overexposed and might have benefited of a dose reduction.
- Published
- 2018
19. Storage at room temperature does not change cisatracurium onset time: A prospective, randomized, double-blind controlled study (vol 31, pg 783, 2012)
- Author
-
Lorne, Emmanuel, Nuzzo, D., Suzanne, S., Walczak, K. -A., Perret, C., Laigle, C., Mattei, N., Dimov, E., Petiot, S., Godart, J., Pila, C., Verdier, M. -C., Chourbaggi, C., Diouf, M., Friggeri, A., Mahjoub, Yazine, Dupont, Hervé, CHU Amiens-Picardie, Simplification des soins chez les patients complexes - UR UPJV 7518 (SSPC), Université de Picardie Jules Verne (UPJV), University of Oxford, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Sénégalais de Recherches Agricoles [Dakar] (ISRA), Service d'anesthésie-réanimation [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de dermatologie [CHU d'Amiens-Picardie], Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), and Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2018
20. Erratum to “Storage at room temperature does not change cisatracurium onset time: A prospective, randomized, double-blind controlled study [Ann. Fr. Anesth. Reanim. 31 (2012) 783–787]
- Author
-
Lorne, E., primary, Nuzzo, D., additional, Suzanne, S., additional, Walczak, K.-A., additional, Perret, C., additional, Laigle, C., additional, Mattei, N., additional, Dimov, E., additional, Petiot, S., additional, Godart, J., additional, Pila, C., additional, Verdier, M.-C., additional, Chourbagi, C., additional, Diouf, M., additional, Friggeri, A., additional, Mahjoub, Y., additional, and Dupont, H., additional
- Published
- 2018
- Full Text
- View/download PDF
21. Population kinetics of factor VIII in mild hemophilia A patients following desmopressin intravenous administration
- Author
-
Leven, C., Guillet, B., Foulquier, J. B., Tron, C., Lemaître, F., Verdier, M. C., Carre, J. L., Bellissant, E., Comets, E., CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Special Issue: SI Meeting Abstract: CO - 062
- Published
- 2017
22. Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole
- Author
-
Petitcollin, A., Crochette, R., Tron, C., Verdier, M.-C., Boglione-Kerrien, C., Vigneau, C., Bellissant, E., and Lemaitre, F.
- Published
- 2016
- Full Text
- View/download PDF
23. Vancomycin collection in heparin plasma tube: is there an influence of heparin on vancomycin concentration?
- Author
-
Boglione-Kerrien, C., Camara, N., Venisse, N., Briand, Y., Tron, C., Petitcollin, A., Taieb, F., Lemaître, F., Bellissant, E., Verdier, M. C, CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract: PM1-039, 20e congrès de la Société Française de Pharmacologie et de Thérapeutique, Nancy, 19-21 avril 2016
- Published
- 2016
24. Sirolimus severe overdosage following co-treatment with the new tablet formulation of posaconazole (Noxafil (R)): a case report
- Author
-
Petitcollin, A., Tron, C., Boglione-Kerrien, C., Deslandes, G., Lemaître, F., Verdier, M. C., Bellissant, E, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract: PM1-007, 20e congrès de la Société Française de Pharmacologie et de Thérapeutique, Nancy, 19-21 avril 2016
- Published
- 2016
25. Managing drug-drug interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir and Mycophenolate mofetil
- Author
-
Tron, C., Lemaître, F., Ben Ali, Z., Leven, C., Jezequel, C., Boglione-Kerrien, C., Verdier, M. C., Guyader, D., Bellissant, E, CHU Pontchaillou [Rennes], Service des maladies du foie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Centre Hospitalier Universitaire [Rennes], Foie, métabolismes et cancer, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies du foie [CHU Rennes], Centre Hospitalier Universitaire [Rennes], Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Jonchère, Laurent
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract: PS-172, 20e congrès de la Société Française de Pharmacologie et de Thérapeutique, Nancy, 19-21 avril 2016
- Published
- 2016
26. Therapeutic drug monitoring of ganciclovir in CMV infections: Should we reassess the therapeutic range?
- Author
-
Tron, C., Arnoult, C., Leven, C., Fillatre, P., Pronier, C., Revest, M., Verdier, M. C., Bellissant, E., Lemaitre, F, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Pharmacologie [Rennes], Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], Fonction, structure et inactivation d'ARN bactériens, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
International audience; Meeting Abstract: PM2-036, 20e congrès de la Société Française de Pharmacologie et de Thérapeutique, Nancy, 19-21 avril 2016
- Published
- 2016
27. Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose
- Author
-
Petitcollin, A., primary, Boglione-Kerrien, C., additional, Tron, C., additional, Nimubona, S., additional, Lalanne, S., additional, Lemaitre, F., additional, Bellissant, E., additional, and Verdier, M.-C., additional
- Published
- 2017
- Full Text
- View/download PDF
28. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies.
- Author
-
Boglione-Kerrien, C., Picard, S., Tron, C., Nimubona, S., Gangneux, J.-P., Lalanne, S., Lemaitre, F., Bellissant, E., Verdier, M.-C., and Petitcollin, A.
- Subjects
HEMATOLOGIC malignancies ,DRUG monitoring ,MEDICATION safety ,DRUG tablets ,PREVENTIVE medicine ,LONGITUDINAL method ,THERAPEUTICS - Abstract
Purpose: Posaconazole is a triazole antifungal widely used for prophylaxis of invasive fungal disease (IFI). Posaconazole tablets allow reaching higher plasma levels than the oral suspension, but safety data with this formulation in real life are scarce. This study aimed at evaluating the safety profile, the pharmacokinetic variability, and the concentration-toxicity relationship of posaconazole tablets in patients with haematological malignancies. Methods: Sixty neutropenic patients treated with posaconazole tablets for prophylaxis of IFI were prospectively included in the study. Adverse drug reactions (ADR) were recorded and analyzed by the Regional Pharmacovigilance Centre to assess posaconazole implication. Blood samples were drawn once a week and plasma trough concentrations ( C ) were assayed by LC-MS/MS. The rates of ADR by quartile of C were compared. Results: Eighteen patients (30%) experienced at least one ADR attributed to posaconazole. Liver function test (LFT) abnormalities were encountered in 20% of patients and resulted in four (6.7%) treatment discontinuations. Posaconazole median (range) C was 1.36 (< 0.1-3.44) µg/mL (inter-patient CV = 43.9%). During follow-up, 28.6% of patients had at least one concentration < 0.7 µg/mL, and 35.7% had at least one concentration > 2 µg/mL. Rates of ADR by quartile of C were not different. Conclusions: Posaconazole was well tolerated; however, LFT abnormalities were frequent. ADR occurrence was not linked to posaconazole exposure. Because posaconazole concentrations were highly variable, TDM can be helpful to avoid underexposure to the drug and increase its efficacy in preventing IFI. Conversely, a large proportion of patients was overexposed and might have benefited of a dose reduction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. La perfusion continue d’oxacilline à doses élevées permet d’atteindre les objectifs pharmacocinétiques souhaités chez les patients admis en réanimation pour médiastinite après chirurgie cardiaque
- Author
-
Malherbe, A., primary, Nesseler, N., additional, Verdier, M.-C., additional, Launey, Y., additional, Piau, C., additional, Flécher, E., additional, Mallédant, Y., additional, and Seguin, P., additional
- Published
- 2014
- Full Text
- View/download PDF
30. Ertapenem in plasma and peritoneal fluid from patients with severe intra-abdominal infections
- Author
-
Verdier, M.-C., primary, Seguin, P., additional, Le Touvet, B., additional, Cady, A., additional, Malledant, Y., additional, and Tribut, O., additional
- Published
- 2011
- Full Text
- View/download PDF
31. Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis
- Author
-
Seguin, P., primary, Verdier, M. C., additional, Chanavaz, C., additional, Engrand, C., additional, Laviolle, B., additional, Donnio, P.-Y., additional, and Malledant, Y., additional
- Published
- 2009
- Full Text
- View/download PDF
32. Assessment of Interindividual Variability of Plasma Concentrations after Administration of High Doses of Intravenous Amoxicillin or Cloxacillin in Critically Ill Patients.
- Author
-
VERDIER, M. C., TRIBUT, O., TATTEVIN, P., MICHELET, C., and BENTUÉ-FERRER, D.
- Published
- 2011
- Full Text
- View/download PDF
33. Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections.
- Author
-
Fily F, Jolivet-Gougeon A, Polard E, Gicquel T, Dupont M, Verdier MC, and Arvieux C
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents adverse effects, Drug Combinations, Enterococcus faecalis, Female, Humans, Male, Middle Aged, Moxifloxacin adverse effects, Propionibacteriaceae, Retrospective Studies, Rifampin adverse effects, Streptococcal Infections, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Gram-Positive Bacterial Infections drug therapy, Gram-Positive Bacterial Infections etiology, Hip Prosthesis adverse effects, Moxifloxacin administration & dosage, Prosthesis-Related Infections drug therapy, Rifampin administration & dosage
- Abstract
Objective: We aimed to describe the effectiveness and safety of the moxifloxacin-rifampicin combination in non-staphylococcal Gram-positive orthopedic implant-related infections., Methods: Patients treated with the moxifloxacin-rifampicin combination for an implant-related infection from November 2014 to November 2016 were retrospectively identified from the database of the referral centers for bone and joint infections in Western France., Results: Twenty-three cases of infection due to Streptococcus spp. (n=12), Cutibacteriumacnes (n=6), and Enterococcus faecalis (n=5) were included. Ten patients with hip prosthesis were included. Infection was polymicrobial in 11 cases. According to the MIC, moxifloxacin was 1.5 to 11.7 times as active as levofloxacin against non-staphylococcal Gram-positive bacteria. We reported an 81.8% success rate, and no severe adverse effect., Conclusion: The moxifloxacin-rifampicin combination is a valuable alternative for the treatment of non-staphylococcal Gram-positive implant-related infections because of the good activity of moxifloxacin against these bacteria and the potential activity on the biofilm., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Colistin-containing cement spacer for treatment of experimental carbapenemase-producing Klebsiella pneumoniae prosthetic joint infection.
- Author
-
Gatin L, Mghir AS, Mouton W, Laurent F, Ghout I, Rioux-Leclercq N, Tattevin P, Verdier MC, and Cremieux AC
- Subjects
- Animals, Arthritis microbiology, Arthritis surgery, Debridement, Disease Models, Animal, Female, Injections, Intra-Articular, Injections, Intramuscular, Klebsiella Infections microbiology, Klebsiella Infections surgery, Prosthesis-Related Infections microbiology, Prosthesis-Related Infections surgery, Rabbits, Treatment Outcome, Anti-Bacterial Agents administration & dosage, Arthritis drug therapy, Carbapenem-Resistant Enterobacteriaceae drug effects, Colistin administration & dosage, Klebsiella Infections drug therapy, Klebsiella pneumoniae drug effects, Prosthesis-Related Infections drug therapy
- Abstract
Carbapenemase-producing Enterobacteriaceae (CPE) are emerging multidrug-resistant bacteria responsible for invasive infections, including prosthetic joint infections (PJIs). Local administration of colistin may provide bactericidal concentrations in situ. This study evaluated the efficacy of a colistin-impregnated cement spacer, alone and in combination with systemic antibiotics, in a rabbit model of CPE-PJI. Elution of 3 MIU of colistimethate sodium (CMS) in 40 g of poly(methyl methacrylate) cement was studied in vitro. In vivo, 5 × 10
8 CFU of KPC-producing Klebsiella pneumoniae (colistin and meropenem MICs of 1 mg/L and 4 mg/L, respectively) were injected close to a prosthetic knee. Surgical debridement and prosthesis removal were performed 7 days later, and rabbits were assigned to six treatment groups (11-13 rabbits each): drug-free spacer; colistin-loaded spacer; colistin intramuscular (i.m.); colistin i.m. + colistin spacer; colistin i.m. + meropenem subcutaneous (s.c.); and colistin i.m. + meropenem s.c. + colistin spacer. Systemic treatment was administered at doses targeting pharmacokinetics in humans, and rabbits were euthanised 7 days later to evaluate bacterial counts in infected bones. In vitro, CMS elution was low (<0.1% at 24 h) but reached a local concentration of ≥20 mg/L (>20 × MIC). In vivo, combinations of local and systemic colistin, with or without meropenem, were the only regimens superior to the control group (P ≤ 0.05) in terms of viable bacterial counts and the proportion of rabbits with sterile bone, with no emergence of colistin-resistant strains. Colistin-loaded cement spacer in combination with systemic antibiotics were the most effective regimens in this CPE-PJI model., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
35. Liposomal amphotericin B pharmacokinetics in a patient treated with extracorporeal membrane oxygenation.
- Author
-
Foulquier JB, Berneau P, Frérou A, Verdier MC, Saint-Marcoux F, Petitcollin A, Tron C, Bellissant E, and Lemaitre F
- Subjects
- Adult, Amphotericin B administration & dosage, Amphotericin B therapeutic use, Antifungal Agents administration & dosage, Antifungal Agents therapeutic use, Antigens, Fungal analysis, Area Under Curve, Bronchoalveolar Lavage Fluid immunology, Female, Galactose analogs & derivatives, Humans, Invasive Pulmonary Aspergillosis diagnostic imaging, Invasive Pulmonary Aspergillosis drug therapy, Liposomes, Mannans immunology, Respiratory Distress Syndrome complications, Amphotericin B pharmacokinetics, Antifungal Agents pharmacokinetics, Extracorporeal Membrane Oxygenation, Invasive Pulmonary Aspergillosis diagnosis, Respiratory Distress Syndrome metabolism, Respiratory Distress Syndrome therapy
- Published
- 2019
- Full Text
- View/download PDF
36. [Storage at room temperature does not change cisatracurium onset time: a prospective, randomized, double-blind controlled study].
- Author
-
Lorne E, Nuzzo D, Suzanne S, Walczak KA, Perret C, Laigle C, Mattei N, Dimov E, Petiot S, Godart J, Pila C, Verdier MC, Chourbagi C, Diouf M, Friggeri A, Mahjoub Y, and Dupont H
- Subjects
- Adult, Aged, Atracurium chemistry, Double-Blind Method, Drug Stability, Endpoint Determination, Female, Humans, Intubation, Intratracheal, Male, Middle Aged, Prospective Studies, Refrigeration, Temperature, Anesthesia, Atracurium analogs & derivatives, Drug Storage, Neuromuscular Nondepolarizing Agents chemistry
- Abstract
Objective: Storage of cisatracurium at room temperature seems to have no effect on its degradation in vitro contrary to the recommendations of storage at +4°C. The purpose of this study was to evaluate the influence of cisatracurium' s storage temperature on its onset time., Study Design: Prospective, randomized, double-blind trial study., Patients and Methods: Thirty patients were enrolled. The control group consisted of 15 patients receiving cisatracurium (0.15mg/kg) stored at room temperature and the intervention consisted of 15 patients receiving cisatracurium (0.15mg/kg) stored at +4°C. The primary endpoint was to compare cisatracurium onset time depending on the storage temperature., Results: Cisatracurium onset time was 235 (180-292) seconds in the "room temperature" group vs. 240 (210-292) seconds in the "refrigerated" group. There was no difference between the onset of cisatracurium depending on the temperature of storage (p=0.51). Subgroups analysis in the "room temperature" group did not show any difference in cisatracurium onset depending on whether it was stored at room temperature for one, two or three weeks. Excellent intubation score was obtained for 100% of the patients., Conclusion: This study demonstrated that cisatracurium's storage at room temperature had no influence on its onset time. It provides an argument for the preservation of cisatracurium at room temperature for a period not exceeding 21 days. Monitoring the onset of curarization may increase the quality score of intubation., (Copyright © 2012. Published by Elsevier SAS.)
- Published
- 2012
- Full Text
- View/download PDF
37. Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients.
- Author
-
Verdier MC, Tribut O, Tattevin P, Michelet C, and Bentué-Ferrer D
- Subjects
- Adult, Aged, Aged, 80 and over, Amoxicillin administration & dosage, Amoxicillin blood, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents blood, Bacterial Infections complications, Bacterial Infections microbiology, Bacterial Infections physiopathology, Cloxacillin administration & dosage, Cloxacillin blood, Creatinine blood, Creatinine metabolism, Drug Administration Schedule, Endocarditis, Bacterial complications, Endocarditis, Bacterial drug therapy, Endocarditis, Bacterial microbiology, Endocarditis, Bacterial physiopathology, Female, Humans, Infusions, Intravenous, Intensive Care Units, Male, Medical Records, Methicillin-Resistant Staphylococcus aureus isolation & purification, Middle Aged, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Streptococcal Infections complications, Streptococcal Infections drug therapy, Streptococcal Infections microbiology, Streptococcal Infections physiopathology, Amoxicillin pharmacokinetics, Anti-Bacterial Agents pharmacokinetics, Bacterial Infections drug therapy, Cloxacillin pharmacokinetics, Renal Insufficiency complications
- Abstract
The aim of the present retrospective observational clinical study was to assess the interindividual pharmacokinetic variability of plasma concentrations of amoxicillin or cloxacillin administered in high doses intravenously in critically ill patients, related to renal function or administration method.Four hundred and two plasma concentrations were measured at steady-state with a high performance liquid chromatography technique in 162 patients treated with 100 - 300 mg/kg/day of intravenous amoxicillin or cloxacillin.For both drugs and administration methods, plasma concentrations were significantly higher for patients with creatinine clearance below 60 ml/min, even though doses were adapted for renal impairment. the correlations calculated between plasma concentrations and creatinine level, creatinine clearance or doses were all low. There were fewer outlying drug concentrations in patients receiving continuous rather than intermittent regimens.Our results are in favor of adapting dosages of these beta-lactam antibiotics based on plasma concentrations, especially in cases of renal impairment.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.